$RGNX
REGENXBIO Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515367340 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q4
Revenue $4.441M $1.140M $1.151M
YoY Change 285.84% 136.02%
Cost Of Revenue $900.0K $44.00K $200.0K
YoY Change 350.0% 266.67%
Gross Profit $3.600M $1.096M $1.000M
YoY Change 260.0% 132.7%
Gross Profit Margin 81.06% 96.14% 86.88%
Selling, General & Admin $4.200M $2.600M $1.100M
YoY Change 281.82% 136.36%
% of Gross Profit 116.67% 237.23% 110.0%
Research & Development $4.812M $5.664M $2.100M
YoY Change 129.14% 422.03%
% of Gross Profit 133.67% 516.79% 210.0%
Depreciation & Amortization $100.0K $0.00 $0.00
YoY Change
% of Gross Profit 2.78% 0.0% 0.0%
Operating Expenses $4.812M $5.664M $3.200M
YoY Change 50.38% 422.03%
Operating Profit -$1.212M -$7.347M -$2.200M
YoY Change -44.91% 331.92%
Interest Expense $300.0K $0.00 -$100.0K
YoY Change -400.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $15.00K
YoY Change -116.3%
Pretax Income -$5.200M -$7.300M -$2.300M
YoY Change 126.09% 305.56%
Income Tax
% Of Pretax Income
Net Earnings -$5.178M -$7.332M -$2.333M
YoY Change 121.95% 308.92%
Net Earnings / Revenue -116.6% -643.16% -202.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$197.7K -$272.4K -$88.80K
COMMON SHARES
Basic Shares Outstanding 26.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.1M $213.3M $1.100M
YoY Change 10272.73%
Cash & Equivalents $54.12M $205.3M $1.121M
Short-Term Investments $60.00M $8.000M
Other Short-Term Assets $851.0K $127.0K $0.00
YoY Change
Inventory
Prepaid Expenses $1.020M $1.400M $28.00K
Receivables $2.136M $609.0K $805.0K
Other Receivables $0.00 $0.00 $800.0K
Total Short-Term Assets $118.1M $215.5M $3.031M
YoY Change 3797.99%
LONG-TERM ASSETS
Property, Plant & Equipment $538.0K $385.0K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $102.5M $11.30M $300.0K
YoY Change 34066.67%
Other Assets $168.0K $128.0K $200.0K
YoY Change -16.0%
Total Long-Term Assets $103.2M $11.83M $460.0K
YoY Change 22341.74%
TOTAL ASSETS
Total Short-Term Assets $118.1M $215.5M $3.031M
Total Long-Term Assets $103.2M $11.83M $460.0K
Total Assets $221.4M $227.3M $3.491M
YoY Change 6241.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.014M $3.105M $334.0K
YoY Change 203.59%
Accrued Expenses $3.200M $1.727M $1.115M
YoY Change 187.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $2.400M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.339M $5.308M $9.189M
YoY Change -52.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $200.0K $0.00
YoY Change
Total Long-Term Liabilities $200.0K $200.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.339M $5.308M $9.189M
Total Long-Term Liabilities $200.0K $200.0K $0.00
Total Liabilities $4.572M $5.506M $9.189M
YoY Change -50.24%
SHAREHOLDERS EQUITY
Retained Earnings -$51.62M -$46.44M -$28.81M
YoY Change 79.18%
Common Stock $269.1M $268.3M $10.52M
YoY Change 2458.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $216.8M $221.8M -$18.29M
YoY Change
Total Liabilities & Shareholders Equity $221.4M $227.3M $3.491M
YoY Change 6241.45%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q4
OPERATING ACTIVITIES
Net Income -$5.178M -$7.332M -$2.333M
YoY Change 121.95% 308.92%
Depreciation, Depletion And Amortization $100.0K $0.00 $0.00
YoY Change
Cash From Operating Activities -$4.400M -$8.400M $100.0K
YoY Change -4500.0% 140.0%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$100.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$144.2M -$19.10M
YoY Change
Cash From Investing Activities -$144.3M -$19.20M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.400M 147.6M 0.000
YoY Change 6050.0%
NET CHANGE
Cash From Operating Activities -4.400M -8.400M 100.0K
Cash From Investing Activities -144.3M -19.20M 0.000
Cash From Financing Activities -2.400M 147.6M 0.000
Net Change In Cash -151.1M 120.0M 100.0K
YoY Change -151200.0% -11009.09%
FREE CASH FLOW
Cash From Operating Activities -$4.400M -$8.400M $100.0K
Capital Expenditures -$100.0K -$100.0K $0.00
Free Cash Flow -$4.300M -$8.300M $100.0K
YoY Change -4400.0% 137.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26313471 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
982000
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
16298000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26306000 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6259000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26306000 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
721000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
268275000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4273000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
221808000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
875000
CY2015Q3 us-gaap Customer Advances Current
CustomerAdvancesCurrent
127000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
73000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
198000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3105000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1727000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46444000
CY2015Q3 us-gaap Liabilities
Liabilities
5506000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
227314000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
850000
CY2015Q3 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
349000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
96000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5308000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
825000
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4999000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2015Q3 us-gaap Assets
Assets
227314000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
224362000
CY2015Q3 us-gaap Trade Receivables Held For Sale Amount
TradeReceivablesHeldForSaleAmount
609000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
18012000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
385000
CY2015Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
11013000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
215485000
CY2015Q3 us-gaap Other Assets Current
OtherAssetsCurrent
127000
CY2015Q3 us-gaap Cost Method Investments
CostMethodInvestments
303000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19038000
CY2015Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8025000
CY2015Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19064000
CY2015Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1400000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205324000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
428000
CY2015Q3 rgnx Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
833000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1119000
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9500000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2645000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
4299000 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10514000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2645000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10518000
CY2014Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2403000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-18291000
CY2014Q4 us-gaap Customer Advances Current
CustomerAdvancesCurrent
153000
CY2014Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
12593000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
334000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1115000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28809000
CY2014Q4 us-gaap Liabilities
Liabilities
9189000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3491000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
3761000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9189000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1423000
CY2014Q4 us-gaap Assets
Assets
3491000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
844000
CY2014Q4 us-gaap Deferred Costs
DeferredCosts
157000
CY2014Q4 us-gaap Trade Receivables Held For Sale Amount
TradeReceivablesHeldForSaleAmount
805000
CY2014Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
327000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2014Q4 us-gaap Assets Current
AssetsCurrent
3031000
CY2014Q4 us-gaap Cost Method Investments
CostMethodInvestments
303000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2014Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
750000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1121000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2537000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.026 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9479000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2643000 shares
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
150000
us-gaap Net Income Loss
NetIncomeLoss
-1667000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2259000
us-gaap Other Operating Income
OtherOperatingIncome
32000
us-gaap Licenses Revenue
LicensesRevenue
3705000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-202000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1097000
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
65000
us-gaap Revenues
Revenues
4972000
us-gaap Interest Paid
InterestPaid
164000
us-gaap Revenue From Grants
RevenueFromGrants
800000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
190000
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-30000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1465000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1667000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-12000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
131000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-774000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
317000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
25000
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
168000
us-gaap Share Based Compensation
ShareBasedCompensation
220000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
592000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-137000
us-gaap Interest Expense
InterestExpense
202000
us-gaap Costs And Expenses
CostsAndExpenses
6437000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2869000
us-gaap Other Noncash Expense
OtherNoncashExpense
1000
us-gaap Related Party Costs
RelatedPartyCosts
741000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-255000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
295000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-1335000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
440000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2732000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
115000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2400000
rgnx Aggregate Licenses Revenue
AggregateLicensesRevenue
3855000
rgnx Imputed Interest On Related Party Debt
ImputedInterestOnRelatedPartyDebt
45000
rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
3600000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Nature of Business</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> REGENXBIO Inc. (the Company) was formed on July&#xA0;16, 2008 in the state of Delaware as ReGenX, LLC, and on December&#xA0;22, 2009, changed its name to ReGenX Biosciences, LLC. On September&#xA0;16, 2014, the Company converted from a limited liability company (LLC) to a C-corporation, and changed its name to REGENXBIO Inc. The Company uses its proprietary NAV<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> Technology platform and collaborates with clinical advisors to advance the development of gene therapy treatments for a range of severe diseases with unmet needs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Initial Public Offering</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On September&#xA0;22, 2015, the Company completed its initial public offering (IPO) whereby the Company sold 7,245 shares of common stock (inclusive of 945 shares of common stock sold by the Company pursuant to the full exercise of an option to purchase additional shares granted to the underwriters in connection with the offering) at a price of $22.00 per share. The shares began trading on the Nasdaq Global Select Market on September&#xA0;17, 2015. The aggregate net proceeds received by the Company from the offering were $145,184, net of underwriting discounts and commissions and offering expenses payable by the Company. Upon the closing of the IPO, all outstanding shares of convertible preferred stock converted into 16,298 shares of common stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Liquidity and Risks</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> As of September&#xA0;30, 2015, the Company has generated an accumulated deficit of $46,444 since inception. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to transition from preclinical manufacturing to commercial production of products.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18072000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y8M12D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3464000 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001590877
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2015-09-22
invest Investment Options Expiration Date
InvestmentOptionsExpirationDate
2014-12-31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
dei Entity Registrant Name
EntityRegistrantName
REGENXBIO Inc.
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
One vote for each share of common stock
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued research and development expenses and the fair value of financial instruments.</p> </div>
dei Trading Symbol
TradingSymbol
RGNX
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3397000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
394000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19065000
us-gaap Net Income Loss
NetIncomeLoss
-17635000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18623000
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
245000
us-gaap Revenues
Revenues
3140000
us-gaap Interest Paid
InterestPaid
7000
us-gaap Revenue From Grants
RevenueFromGrants
305000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
140000
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-327000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
618000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17638000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
128000
us-gaap Other Operating Income
OtherOperatingIncome
26000
us-gaap Licenses Revenue
LicensesRevenue
635000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-200000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
127000
us-gaap Investment Income Net
InvestmentIncomeNet
23000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-41000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1372000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17661000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-750000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
34000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
200000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1389000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
4000
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
-26000
us-gaap Share Based Compensation
ShareBasedCompensation
2059000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
120000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1747000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
204203000
us-gaap Interest Expense
InterestExpense
20000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7671000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
111392000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
94000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
317000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19459000
us-gaap Costs And Expenses
CostsAndExpenses
20778000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
241734000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12471000
us-gaap Related Party Costs
RelatedPartyCosts
527000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-34000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
758000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-3412000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
148233000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
43000
rgnx Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
759000
rgnx Aggregate Licenses Revenue
AggregateLicensesRevenue
2635000
rgnx License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
250000
rgnx Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
198000
rgnx Imputed Interest On Related Party Debt
ImputedInterestOnRelatedPartyDebt
13000
rgnx Conversion Of Related Party Accrued Service Fees To Convertible Preferred Stock
ConversionOfRelatedPartyAccruedServiceFeesToConvertiblePreferredStock
2403000
rgnx Milestone Fee Payments Upon Submission Preclinical Filings
MilestoneFeePaymentsUponSubmissionPreclinicalFilings
500000
rgnx Milestone Fee Payments Upon Commencement Of Clinical Trials
MilestoneFeePaymentsUponCommencementOfClinicalTrials
20000000
rgnx Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings
11300000
rgnx Milestone Fee Payments Upon Approval Of Commercial Products
MilestoneFeePaymentsUponApprovalOfCommercialProducts
51500000
rgnx Outstanding Common Stock Holders Right To Elect Number Of Directors
OutstandingCommonStockHoldersRightToElectNumberOfDirectors
1 Directors
rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
2000000
rgnx Milestone Fee Payments Upon Achievement Of Specified Sales Targets
MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets
2000000
rgnx Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingInAccountsPayableAndAccruedExpenses
2431000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.026 pure
CY2014 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9479000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2643000 shares
CY2014Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
150000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1793000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1919000
CY2014Q3 us-gaap Revenues
Revenues
483000
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
310000
CY2014Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
150000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1701000
CY2014Q3 us-gaap Other Operating Income
OtherOperatingIncome
8000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-92000
CY2014Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1793000
CY2014Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
23000
CY2014Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
126000
CY2014Q3 us-gaap Interest Expense
InterestExpense
92000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
2184000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1085000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1070000
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12000
CY2014Q3 rgnx Aggregate Licenses Revenue
AggregateLicensesRevenue
150000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y3M18D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3464000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4809000 shares
CY2015Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1000000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-7332000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7332000
CY2015Q3 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
65000
CY2015Q3 us-gaap Revenues
Revenues
1140000
CY2015Q3 us-gaap Revenue From Grants
RevenueFromGrants
14000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7347000
CY2015Q3 us-gaap Other Operating Income
OtherOperatingIncome
5000
CY2015Q3 us-gaap Licenses Revenue
LicensesRevenue
65000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
CY2015Q3 us-gaap Investment Income Net
InvestmentIncomeNet
15000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7358000
CY2015Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
61000
CY2015Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
56000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
8487000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5664000
CY2015Q3 us-gaap Related Party Costs
RelatedPartyCosts
213000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2567000
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
44000
CY2015Q3 rgnx Aggregate Licenses Revenue
AggregateLicensesRevenue
1065000
CY2015Q3 rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
1000000

Files In Submission

Name View Source Status
0001193125-15-367340-index-headers.html Edgar Link pending
0001193125-15-367340-index.html Edgar Link pending
0001193125-15-367340.txt Edgar Link pending
0001193125-15-367340-xbrl.zip Edgar Link pending
d64870d10q.htm Edgar Link pending
d64870dex311.htm Edgar Link pending
d64870dex312.htm Edgar Link pending
d64870dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgnx-20150930.xml Edgar Link completed
rgnx-20150930.xsd Edgar Link pending
rgnx-20150930_cal.xml Edgar Link unprocessable
rgnx-20150930_def.xml Edgar Link unprocessable
rgnx-20150930_lab.xml Edgar Link unprocessable
rgnx-20150930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending